GAIA-102 (fulamleucel) (iv)
Non-Small Cell Lung Cancer (NSCLC)
Early clinical trialActive
Key Facts
Indication
Non-Small Cell Lung Cancer (NSCLC)
Phase
Early clinical trial
Status
Active
Company
About GAIA BioMedicine
A biotech company developing off-the-shelf, non-genetically modified NK-like cell therapies to eliminate solid tumors.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| Idylla EGFR Mutation Assay | Biocartis | Approved |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| Macrocyclic OMNI-EGFR Inhibitor | BlossomHill Therapeutics | Phase 1 |
| TUMORIN Clinical Trial | Nilogen Oncosystems | N/A (Diagnostic Validation) |
| Membrex™ | Metaclipse Therapeutics | Pre-clinical |
| Lazertinib (Leclaza) | Genosco | Approved |
| IPH5201 (anti-CD39 mAb) | Orega Biotech | Phase 2 |
| Platin-DRP® | Chosa Oncology | Validation |
| Undisclosed RNA Immunotherapy | Epitopea | Pre-clinical |
| Aspyre Clinical Test for Lung | Biofidelity | Commercial |
| EGFR Mutation Detection Assay | Stilla Technologies | Assay Development/Validation |